Tag: Tequin

A study in *The New England Journal of Medicine* found patients taking gatifloxacin had a 17-fold increased likelihood of hyperglycemia. This article explains **why is gatifloxacin banned** and details the severe risks that led to its market withdrawal for systemic use.

In 2006, the manufacturer of the antibiotic Tequin (gatifloxacin) voluntarily withdrew its oral formulation from the market following reports linking it to severe and potentially fatal blood sugar abnormalities. This action was later officially recognized by the FDA as a withdrawal for reasons of safety and effectiveness. The critical question of **Why was gatifloxacin banned?** is answered by examining the drug's serious metabolic risks.